- Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients
This study is testing a new cell therapy (TX200-TR101) for kidney transplant patients. It aims to see if this treatment can help prevent the body from rejecting the new kidney and is safe to use. This is the first time this treatment is being given to people.
For: Prophylaxis against renal transplant rejectionBelgium · Netherlands - Active not recruitingPHASE1, PHASE2
Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
This study looks at a new treatment called TX200-TR101 for people getting a kidney transplant from a living donor. It aims to help the body accept the new kidney and prevent it from being rejected. Researchers want to check if it's safe and how well it works.
For: Kidney Transplant Rejection · End Stage Renal DiseaseBelgium · Netherlands · United Kingdom